Text Size
21 studies found for:    " March 14, 2012":" April 13, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
" March 14, 2012":" April 13, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: darunavir/cobicistat/emtricitabine/GS-7340;   Drug: darunavir + cobicistat + emtricitabine/tenofovir df
2 Recruiting Project RETAIN: Providing Integrated Care for HIV-Infected Crack Cocaine Users
Conditions: HIV;   AIDS;   Substance Abuse
Intervention: Behavioral: Retention Clinic
3 Terminated The Mochudi Prevention Project ART Protocol
Condition: HIV Infections
Intervention: Drug: highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine
4 Recruiting Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)
Condition: HIV Infection
Interventions: Drug: Tenofovir, Emtricitabine, Lopinavir/r;   Drug: Tenofovir, Emtricitabine, Raltegravir
5 Active, not recruiting Part A: Drug Interaction Study of GS-7977 and Antiretroviral Therapy(ART) Combinations in Human Immunodeficiency Virus and Hepatitis C Virus (HIV/HCV) Co-infected Patients. Part B: Phase 2, Open-Label Study to Investigate Efficacy and Safety of GS-7977 for 12 Weeks in HIV/HCV Co-infected Patients.
Conditions: Hepatitis C;   HIV
Interventions: Drug: GS-7977;   Drug: Efavirenz (EFV);   Drug: Tenofovir (TDF);   Drug: Emtricitabine (FTC);   Drug: Atazanavir/ritonavir (ATV/r);   Drug: Zidovudine (ZDV);   Drug: Lamivudine (3TC);   Drug: Darunavir/ritonavir (DRV/r);   Drug: Raltegravir (RAL);   Drug: Ribavirin (RBV);   Drug: Peginterferon Alfa 2a (PEG)
6 Active, not recruiting Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
Condition: HIV Infections
Interventions: Biological: GEO-D03 DNA vaccine;   Biological: MVA/HIV62B (MVA62B) vaccine;   Biological: Placebo for GEO-D03 DNA;   Biological: Placebo for MVA62B:
7 Recruiting Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: HIV-MAG vaccine;   Biological: IL-12 pDNA adjuvant;   Biological: VSV HIV gag vaccine;   Biological: Placebo
8 Completed A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: DTG;   Drug: BCV;   Drug: TVR
9 Active, not recruiting Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: dolutegravir 50 mg twice daily;   Drug: dolutegravir placebo twice daily;   Drug: Open-label dolutegravir 50mg twice daily
10 Recruiting Intervention to Improve Engagement in Care Among Newly Diagnosed HIV-positive Men
Conditions: HIV;   Patient Compliance
Interventions: Behavioral: Positive Choices;   Behavioral: Personalized Cognitive Counseling
11 Recruiting Cell Phone Messaging to Improve Communication of Critical Laboratory Results to Patients in Rural Uganda
Conditions: HIV;   Tuberculosis
Intervention: Other: Cellular Phone Text Message Formats
12 Recruiting Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
Condition: HIV
Intervention: Drug: Tesamorelin for injection
13 Completed Experimental Analysis of HIV Risk Assessment Reactivity in South African Clinics
Condition: HIV Prevention and Assessment Reactivity
Interventions: Behavioral: Detailed baseline interview, enhanced HIV intervention;   Behavioral: General baseline interview, enhanced HIV intervention;   Behavioral: No baseline interview, enhanced HIV intervention;   Behavioral: Detailed baseline interview, standard of care intervention;   Behavioral: General baseline interview, standard of care intervention;   Behavioral: No baseline interview, standard of care intervention
14 Recruiting A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy
Condition: HIV-associated Myelopathy
Interventions: Drug: Intravenous Immunoglobulin;   Drug: Placebo
15 Recruiting The Rilpivirine Cerebrospinal-fluid (CSF) Study
Condition: HIV
Intervention: Drug: Rilpivirine
16 Enrolling by invitation Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV
Conditions: Tobacco Use Cessation;   Tobacco Cessation;   Tobacco Use Disorder;   Tobacco Dependence;   Tobacco-Use Disorder;   Virus, Human Immunodeficiency
Interventions: Behavioral: Web-Based Tailored Smoking Cessation Intervention;   Behavioral: Standard of Care
17 Recruiting Reducing Drug Use and HIV Risk in Drug-dependent Adults Arrested for Prostitution
Conditions: Substance-related Disorders;   HIV Risk Behavior
Interventions: Behavioral: Therapeutic Workplace;   Drug: Methadone;   Drug: Buprenorphine
18 Recruiting Prediction and Pathogenesis of the Immune Reconstitution Inflammatory Syndrome
Conditions: Immune Reconstitution Inflammatory Syndrome;   Opportunistic Infections
Intervention:
19 Not yet recruiting Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection
Condition: Cryptococcal Infection Disseminated
Interventions: Drug: Flucytosine and fluconazole;   Drug: Fluconazole
20 Recruiting Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies
Conditions: Anal Cancer;   Cervical Cancer;   Lung Cancer;   Lymphoma;   Nonneoplastic Condition
Interventions: Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Other: biologic sample preservation procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: medical chart review
To Top

Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results
† Indicates status has not been verified in more than two years